KRAS and neoplasm: We found that persistent high expression of SIAH in residual tumors reflects activation of the “tumor-driving” K-RAS/SIAH/EGFR pathway that fuels tumor growth and metastatic spread of disseminated and residual chemo-resistant tumor clones remaining after NACT (Figure 1B–E) [276].